SGLT2 Inhibition in the Comorbid CKD patient
Published: 22 February 2022
4m 26sPart 3 Discussion and Q&A
At e-SPACE CRM 2022 clinical data was analysed through a practical lens to address questions around SGLT2 inhibitor use in CKD.
Explore the data-supported discussion of the treatment landscape for patients with CKD, and other comorbidities. The inciteful conversation is led by Dr Muthiah Vaduganathan (Chair) and Professor Mustafa Arici.
This educational symposium will increase delegates' understanding of:
- SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
- Data supporting the cardiorenal efficacy of SGLT2 inhibition in comorbid patients with CKD
- How clinical data from SGLT2 inhibitor trials should be applied in clinical practice
More from this programme
Welcome and Introductions
|Welcome and Introductions||Watch now|
Clinical data through a practical lens
Discussion and Q&A
|Discussion and Q&A||Watch now|
Dr Vaduganathan is a Cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He is a co-chair of a Heart Failure Collaboratory committee focused on improving future clinical trials in heart failure, and serves on the planning committee of the Global CardioVascular Clinical Trialists Forum. He is a Section Editor of the Fellows-in-Training / Early Career section of JACC, Associate Editor of JACC Heart Failure, and serves on the editorial board of the European Journal of Heart Failure. His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies, and he has authored or co-authored more than 500 peer-reviewed publications. He participates on study leadership and on committees of ongoing advanced-phase trials in cardiometabolic medicine and heart failure.…